3D printing (or additive manufacturing) has become an innovative driving force in orthotics and prosthetics (O&P), allowing for highly customized, precise, and affordable solutions. 3D printing also reduces production time, enabling rapid prototyping and faster turnaround for patients, which can be particularly beneficial for growing children or those requiring adjustments. Although traditional methods are still widely used, more clinicians increasingly integrate 3D printing into their daily practices as the economics of using 3D technologies improves. Furthermore, because 3D printing can be performed in-house or locally, logistics costs and lead times are reduced, providing patients faster service and fewer fitting sessions. For practitioners and clinics, this means a more efficient business model, allowing for a quicker return on investment, lower overhead, and the ability to affordably serve a growing number of patients. Join us for our annual 3DHEALS O&P event and a panel of experts from the clinics, industry, startup, and non-profit organizations. Explore where the next growth opportunity is. We will also use this opportunity to fundraise for our non-profit organization Victoria Hand Project.

Apply to speak or sponsor the event: info@3dheals.com

Subscribe here to receive event emails.

Speakers:

Drew Meyer MSPO, CPO

Drew Meyer, MSPO, CPO, has eight years of experience in clinical orthotics and prosthetics and four years in medical device design, underpinned by a background in biomedical engineering. He holds degrees from the Colorado School of Mines and Baylor College of Medicine. Throughout his career in the O&P industry, Drew has held various roles, from staff practitioner, to clinic manager, and now developing and selling software solutions that enhance the designs and efficiency of orthotic and prosthetic care. Outside of his professional life, Drew is dedicated to his family. He has been married for 11 years and is actively involved in raising their four beautiful children. This balance of a demanding family life and a professional career in orthotics and prosthetics highlights his commitment to both personal and professional growth, and underscores his dedication to enhancing patient outcomes through innovative technology.

Joe Fairley

Joe Fairley is a Certified Prosthetist and entrepreneur with a decade of experience in applying additive manufacturing to the Orthotics and Prosthetics field. He is the owner of Ascent Fabrication – which distributes large format FDM and FGF 3D printers, premium materials, and provides installation training, ongoing troubleshooting, and product development services. Over the last three years, Ascent Fabrication has played an integral role in assisting the adoption of additive manufacturing and a digital workflow in the O&P field. Joe is currently a Business Development Manager on the Digital Services team at PROTEOR, developing automatic workflows for 3D printing through their FlySHAPE software application, an extension of the ORTEN software suite. Their aim is to provide a powerful, yet simple solution to take a raw 3D scan of a patient’s limb and apply custom templated clinical modifications, then automate device design and .gcode creation for 3D printing.

Melanie Shelton

Melanie Shelton has nearly two decades of experience in the O&P industry. Her expertise spans from establishing and overseeing distributorships for orthotic fabrication equipment across Europe, the Middle East, and Southeast Asia, to account management, Crisis Communications, Marketing and clinical support. In her previous role at HP, she spearheaded the development and adoption of the Arize Orthotic Solution for four years, demonstrating her commitment to innovation and digital workflow automation. She is currently leading HP’s efforts to advance 3D printing adoption and manufacturing efficiency in the O&P Industry. Her depth of experience and record of success in technological advancement in the O&P arena point to her commitment to help drive the industry forward.

Michael Peirone

Michael Peirone began his journey with Victoria Hand Project as a co-op student, where he quickly fell in love with the mission of creating life-changing prosthetic care for people in need. While completing his Biomedical Engineering degree at the University of Victoria, Michael continued to volunteer and work on projects with VHP, including a second co-op in Nepal that proved deeply inspiring, allowing him to witness the profound impact of the work firsthand.

After graduating, Michael joined VHP full-time as a Biomedical Systems Designer, where he continued to grow within the organization, later serving as COO before stepping into his current role as CEO. His work with VHP has taken him around the world, including a recent trip to Ukraine in June 2023 to support prosthetic care for those affected by the war. His journey reflects a commitment to innovation in healthcare and a passion for making a lasting difference in the lives of amputees worldwide.

Evan Eckersley

Evan holds degrees in Bioengineering and Finance from Lehigh University’s IBE program with a strong focus on customer-centric design and innovation. Previously, he applied his experience in protein engineering and synthetic biology as founder and COO of Lytos Technologies. At Lytos, he led R&D and commercialization efforts of an engineered enzymatic fungicide for crop protection, biomanufacturing scale-up, fundraising, and regulatory. At Icarus, he has applied his operational and biomanufacturing experience to scale Icarus’ digital and additive fabrication system to rapidly deliver highly customized devices on a mass scale while ensuring a high-quality customer experience from sales through manufacturing. He oversees company finance, marketing, regulatory and clinical research efforts. Evan is passionate about Icarus’ mission to deliver better outcomes with functional, highly-personalized devices through the combination of advanced digital and additive technologies while maximizing access to patients in need with innovative go-to-market strategies.

Moderator:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Sponsor:

This annual virtual event dedicated to biomaterials and material science for 3D printing implants, medical devices, and biofabrication presents a unique and compelling opportunity for individuals across various disciplines to delve into the cutting-edge advancements shaping the future of healthcare. With the demand for innovative solutions in implantology and tissue engineering on the rise, this event serves as a pivotal platform for researchers, engineers, clinicians, entrepreneurs, and industry professionals to explore the latest breakthroughs and methodologies in biomaterials science. Attendees will have the chance to gain invaluable insights into the development of novel materials, fabrication techniques, and biofunctionalization strategies tailored for applications in 3D printing implants, medical devices, and biofabrication. From elucidating the fundamental properties of biomaterials to showcasing innovative approaches for enhancing biocompatibility, mechanical properties, and bioactivity of implants, this event offers a comprehensive overview of the current state-of-the-art in material science for medical applications. Moreover, the virtual format ensures accessibility to a global audience, facilitating networking opportunities and knowledge exchange among professionals from diverse backgrounds and regions.

Apply to speak or sponsor the event: info@3dheals.com

Subscribe here to receive event emails.

Speakers:

Rao Bezwada

An accomplished scientist and entrepreneur, Rao S. Bezwada, Ph.D. established Bezwada Biomedical, an innovation-based and technology-driven research company, in 2003. The company is focused on developing a wide range of novel absorbable polymeric biomaterials to enhance quality of life by producing next generation bioabsorbable medical devices with therapeutic applications. Dr. Bezwada earned a doctorate in chemistry from the Stevens Institute of Technology in New Jersey and has over 40 years of research experience in the medical device industry, including 20 years of service at Ethicon, Inc. (a Johnson & Johnson Company). While at Ethicon, Dr. Bezwada’s research and development efforts led to the launch of a number of products, including Monocryl®, a new ultra-pliable synthetic absorbable monofilament suture. This product has represented worldwide sales of more than two (2) billion dollars since its launch in 1993 and current annual sales of over 100 million dollars. In recognition of this invention, along with its development, Johnson & Johnson, Inc. awarded Dr. Bezwada the prestigious Johnson Medal in 1996. Dr. Bezwada has been a prolific inventor and has been issued more than 135 U.S. patents on absorbable polyurethanes, absorbable amino acid polymers, absorbable polyester amides, absorbable polyoxaesters, and controlled release polymers. FDA-approved products such as MONTAGE® Putty, MONTAGE Fast Set Putty, Montage Flowable Putty, and PERMATAGE Putty, marketed by Abyrx for wound healing and bone applications, are based on Bezwada Biomedical’s absorbable polyurethane technology. Dr. Bezwada has also pioneered specialty bio-inks for 3D printing applications. In addition to his passion for science and technical accomplishments, Dr. Bezwada has also established a non-profit organization, Society for Basic Needs, in India. This organization has a mission aimed at improving the quality of life for those less fortunate by providing them with essential amenities and opportunities for health and education.

Mohammad Albanna, PhD

Dr. Albanna is the founder and CEO of Humabiologics, one of the only regenerative medicine companies focused on developing and commercializing human-derived biomaterials to researchers around the world for regenerative medicine applications. He holds a PhD in Biomedical Engineering, 2 master’s degrees in Materials Sciences and Electrical & Computer Engineering and completed a postdoctoral fellowship at Wake Forest Institute of Regenerative Medicine, where he served as the lead of the skin bioprinting group and is currently an adjunct assistant professor of Surgery at Atrium Health Wake Forest Baptist. Dr. Albanna authored several peer-reviewed papers, book chapters and is the inventor of several issued and patent-pending applications. Dr. Albanna has 15 years of industry experience, during which he has held several senior and executive leadership positions across several industries including medical devices, blood banking, and tissue banking. His work in regenerative medicine was recognized through several prestigious awards including 2013 Thomas Edison Gold Award in Innovation, 2018 Arizona Innovator of the year finalist, and 2021 Arizona Leader in Innovation Award.

Anis Hadj Henni

As CEO, Anis Hadj Henni oversees Rheolution’s development strategy over the Life Sciences and Agri-Food business units. He is also in charge of the customer experience and key partnerships with strategic business partners, distributors and investors. Anis works closely with Rheolution’s sales, operations and engineering teams to provide the best instruments, software and services to customers. As an entrepreneur, Anis is driven by a powerful purpose: ‘‘My team and I are on the mission of ending the status quo in the analytical testing space that limits our customer’s ability to innovate and create value for the benefit of people’s health and nutrition. We are defining, with our community of users, Soft Matter Analytics as the paradigm that will shape the future of analytical instrumentation. And, because an idea is not enough, we gathered an outstanding and talented team that works hard to make Soft Matter Analytics a realty to our customers and communities’’, he says. After a successful career in research, Anis co-founded Rheolution in 2009 with new ideas and a vision of what the future could look like. A decade after, he is extremely proud of seeing customers, colleagues, business partners and stakeholders sharing, enriching and building that vision. Anis graduated in civil engineering from the National Polytechnic School of Algiers (Algeria) and holds a Ph.D. in mechanics from Université de Bordeaux (France).

Annaliese Vojnich

Meet Annaliese Vojnich, a dynamic business development and technical sales manager currently overseeing the Puredyne® brand and the Hygienic Solutions division for ViscoTec America. Annaliese’s professional journey spans various industries, including sales, pharmaceuticals, medical technology, research and development, and hygienic FDA manufacturing, equipping her with a versatile skill set that stands at the forefront. Earning a bachelor’s degree in Dietetics/Nutritional Sciences from the esteemed University of Georgia in 2018, Annaliese’s academic foundation underscores her commitment to knowledge and growth. Her pursuit of education extended further with a Certificate in Women’s Entrepreneurship from Cornell University, where she refined her leadership abilities in 2022. Annaliese’s passion for biotechnology began in 2014 at the Center for Applied Genetic Technologies, a University of Georgia facility. During her time as an assistant lab manager and research assistant, her responsibilities were concentrated on genetic transformation, somatic embryogenesis, plant breeding and genetics, and tissue culture management. Annaliese’s foundation has positioned her to excel not only in sales and management roles but also in bridging the gap between innovation and real-world applications. Her current role at ViscoTec America, where she contributes to cutting-edge dosing technology and bioprinting advancements, showcases her ability to merge her passion for science with her sales acumen.

Ferry Melchels

Ferry Melchels is the research professor of Biomaterials and Tissue Engineering at the Future Industries Institute at the University of South Australia in Adelaide. His main interests lie in polymeric biomaterials for 3D printing, tissue engineering, and drug and vaccine delivery. His work has been published in leading journals, attracting over 17,000 citations. He is a recipient of the Patrick Neill Medal for Early Career Researchers in the Life Sciences from the Royal Society of Edinburgh (2020), and the Mid-Career Investigator Award from the International Society for Biofabrication (2019). Ferry holds an MSc (2005) in chemical engineering and PhD (2010) in biomaterials from the University of Twente (The Netherlands). He was a Marie Curie post-doctoral fellow between two of the pioneering institutes in Biofabrication; Queensland University of Technology (Brisbane, Australia) and University Medical Center Utrecht (The Netherlands) and held his first PI position at Heriot-Watt University in Edinburgh (UK) from 2015-2023. Besides home brewing the best beers on the weekend, his future aim is to continue advancing materials-based technology platforms for biomedical applications.

Moderator:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Now on Demand:

Subscribe here to receive event emails.

Thanks to Our Sponsors:

One key player in the 3D technology space in medicine is AR/VR/MR (augmented reality, virtual reality, mixed reality). Parallel to the advancement of 3D printing, but on a somewhat divergent path, these technologies are increasingly popular with clinical end users, with applications ranging from education, telemedicine, surgical planning, intra-operative guidance, and even immersive therapy for mental illness. With the premiere of many new, more user-friendly hardware supporting AR/VR/MR from the big tech and the rising force of artificial intelligence, these technologies are no longer just complementary; they are becoming a force to be reckoned with in future healthcare. Join this exciting event, where we invite innovators, clinicians, researchers, and entrepreneurs to showcase the almost infinite possibilities in which these technologies drive innovation and improve healthcare outcomes. You are not going to get this content elsewhere. 

Apply to speak or sponsor the event: info@3dheals.com

Subscribe here to receive event emails.

Speakers:

David Pearlstone

Dr. Pearlstone is a founder/principal and CEO of DICOM Director. LLC. Previously, he was Executive Director of HealthHavenHub, a digital healthcare incubator in New Haven, CT,. Prior to that, Dr. Pearlstone had a long career in academic medicine, previously serving as Medical Director for Vitas Healthcare of Connecticut, Director of Breast Services at Hackensack University Medical Center, and Associate Chairman of Surgery, Chief of Surgical Oncology, and Director of Surgical Research at Lincoln Hospital in New York City and as Assistant Professor of Surgery at Yale School of Medicine, Dr. Pearlstone graduated from Phillips Exeter Academy and received his B.Sc. with Honors from Vanderbilt University in Nashville, Tennessee. Following a research fellowship at the Howard Hughes Medical Institute at Vanderbilt, he received his MD from New York University in 1989. He completed his residency in general surgery at NYU, including two years as a Clinical Research Fellow at Memorial Sloan-Kettering. He then went on to complete a clinical fellowship in surgical oncology at the M. D. Anderson Cancer Center in Houston, Texas. Dr. Pearlstone has worked in biomedical technology transfer since 2002, serving on the faculty of Clemson University College of Engineering in Clemson, SC, and the Stevens Institute of Technology in Hoboken, NJ. In 2010, Dr. Pearlstone received his MBA from the Leadership in Healthcare program at the Yale University School of Management.

Jesse Courtier, MD

Dr. Jesse Courtier, MD, is the Chief of Pediatric Radiology at UCSF Benioff Children’s Hospital, San Francisco, and a Clinical Professor in the UCSF Department of Radiology & Biomedical Imaging. Dr. Courtier is a multi-award-winning educator and innovator and recipient of the UCSF Catalyst Award in Digital Health. He is founder of Sira Medical, a venture-backed UCSF spinout company focusing on the use of Augmented Reality for improved pre-surgical planning, medical education, and training. Dr. Courtier has authored more than 70 peer reviewed articles with more than 2500+ citations. His interests lie in the application of Augmented Reality and other new innovative technologies for the improved care of Pediatric patients.

Justin Sutherland

Justin Sutherland, CEO and co-founder of Realize Medical, began his career as a medical physicist at the Ottawa Hospital and as an assistant professor in the department of radiology at the University of Ottawa. Fueled by his passion for the transformative potential of mixed reality in medicine, he spun out Realize Medical based on the ground-breaking medical virtual reality research conducted at the hospital. With their FDA-cleared medical VR platform, Elucis, Justin and the Realize Medical team are enhancing the field of medicine and procedure planning, driving towards more efficient and accurate patient care and surgical outcomes.

Evan Derman

Evan Derman is the Chief Operating Officer and Co-founder of Thyng, an Augmented Reality company dedicated to pioneering the next generation of healthcare solutions. Leveraging advanced 3D visualization technologies, Thyng has developed MedReality, a suite of healthcare products designed to revolutionize medical training, education, and patient care. With a strong foundation in business operations and a keen interest in technological advancements, Evan has been pivotal in shaping Thyng’s strategic vision and operational success. His leadership and commitment to enhancing healthcare through AR technology continue to position MedReality at the forefront of the industry.

Susan Persky

Dr. Susan Persky is an associate investigator within the Social and Behavioral Research Branch (SBRB) at the National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH). She is the founding director of the Immersive Simulation Program (ISP) – an emerging tech research lab, founded in 2006. Dr. Persky has published extensively in the areas of health communication, genomics, and virtual reality methods and application. She has provided scientific leadership through service on bodies such as the World Economic Forum Global Future Council on Virtual and Augmented Reality and the Veteran’s Administration Immersive Executive Round Table. Dr Persky has presented her research in venues such as the Smithsonian Institution and the National Academies of Sciences, Engineering and Medicine.

Moderator:

Rick Beberman

Rick Beberman is co-founder and Chief Executive Officer of Sira Medical. Sira develops augmented reality software for pre-operative planning patient education and training. Sira’s software saves over 20% of operating room times, and makes surgery safer and more efficient. The company’s technology originated at the University of California, San Francisco (UCSF) and is FDA 510(k) cleared. Rick has been involved in digital health for fifteen years as an entrepreneur, business development executive and board member. Prior to healthcare, Rick was an investment banker specializing in mergers and acquisitions advisory, capital raising, and partnerships. Rick has an MBA from New York University and a master’s degree in accounting from the University of Southern California.

Now on Demand:

This virtual event centered on biofabrication and bioprinting of musculoskeletal tissue. As the demand for effective treatments for bone and cartilage defects continues to rise with an aging population, this event is a vital platform for deep conversations about the challenges, progress, and future of tissue engineering for regenerative purposes in treating orthopedic diseases. By attending, participants will gain invaluable insights into the cutting-edge technologies and methodologies driving the development of innovative treatments for musculoskeletal diseases. Throughout the event, attendees will have the chance to engage with leading experts in the field, who will share their expertise and firsthand experiences in both the scientific and commercialization aspects of the field.  Moreover, the virtual format ensures accessibility to a global audience, fostering collaboration and knowledge exchange among professionals from diverse backgrounds and regions. Don’t miss your chance to be part of this transformative event shaping the future of musculoskeletal tissue engineering and regenerative medicine.

Note: If you can’t make it on time, you can register and watch the conversation on-demand for a week after the live event ends.

Live event participation is FREE to all public.

You can subscribe here to receive future emails.

Apply to speak or sponsor the event: info@3dheals.com

Speakers:

Y. Shrike Zhang

Dr. Zhang is an Associate Professor in the Department of Medicine at Harvard Medical School and Associate Bioengineer in the Division of Engineering in Medicine at the Brigham and Women’s Hospital. He is directing the Laboratory of Engineered Living Systems (www.shrikezhang.com), where the research is focused on innovating medical engineering technologies, including 3D bioprinting, organs-on-chips, microfluidics, and bioanalysis, to recreate functional tissues and their biomimetic models, for applications in regenerative medicine and personalized medicine. Dr. Zhang is an author of >330 peer-reviewed publications (>50 covers; citations ~35,000, h-index = 92). His scientific contributions have been recognized by >45 awards.

Brad Estes

Dr. Estes received his Ph.D. from Duke University in Biomedical Engineering with an emphasis in chondrogenesis of fat-derived stem cells. Before earning his Ph.D., Brad served as the Manager of Research and Development in the spinal orthopedic division of Medtronic where he oversaw commercialization of medical devices from conception to market, including the achievement of regulatory approval for class III medical devices. He was also integrally involved in seeking intellectual property protection for the innovative products Medtronic was producing. In addition, Dr. Estes has acted as a consultant for both small and large medical device companies. In total, he has over 25 years of industry experience and holds 55 patents associated with medical devices. In his current role, Brad oversees all aspects of CytexOrtho operations with a focus on growth and success. In this position, he provides strategic leadership and sets the vision and direction for the company. His responsibilities include guiding research and development efforts, forging strategic partnerships, securing funding, and ensuring regulatory compliance. Additionally, he plays a hands-on role in fostering a collaborative and dynamic work culture, driving motivation and creativity among the tight-knit team at CytexOrtho.

Flore-Anne Poujade

Dr. Poujade earned her PhD from the University of Hull, UK. During her academic career, she worked on several projects. Including deciphering the roles of growth factors and hypoxia in regulating chondrocytic phenotype in vitro, as well as creating an aorta on a chip model to better understand the mechanisms driving ascending aortic aneurysm. It was after her postdoc at the Karolinska Institute that she joined CELLINK where she now works as Senior Field Application Scientist. As such, over the past 3 years, she has advised numerous researchers on 3D bioprinting techniques and practices to help democratise the fabrication of more realistic research models.

Dr. Wilson Wong

Wilson is a healthcare-focused entrepreneur with a PhD, MPhil, and BEng from the University of Hong Kong, specializing in biomechanics, biomaterials, and bone-related diseases. He also completed technopreneurship training at IECT, University of Cambridge, supported by Dr. Hermann Hauser. In 2014, he founded NOVUS Life Sciences Limited, where he currently serves as Chairman and CEO. NOVUS, a global leader in 3D printing biomaterials, operates cutting-edge manufacturing facilities in Hong Kong and Shenzhen. The company supplies to 35+ countries and 65+ corporate clients, supporting the production of patient-specific implants and devices. Wilson is actively engaged in the startup ecosystem and dedicated to fostering entrepreneurship education. He has been a featured speaker and lecturer at institutions and Bloomberg. Under his leadership, NOVUS has received numerous prestigious awards, including Champion of IMAGINE IF!, CNBC’s hottest startups, and accolades from GIN Austria, French Tech Ticket, and Alibaba Jumpstarter.

Moderator:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Exclusive Interviews with Our Speakers:

Now on Demand:

Subscribe here to receive event emails.

Our Sponsor For This Event:

In-silico simulation refers to using computer modeling and simulations to predict the behavior of biological systems or processes. It is an increasingly important concept for future medical device and drug development. The benefits of in-silico simulation include lowering costs, reducing animal testing, improving accuracy and safety, and clarifying regulatory pathways. This virtual event aims to illuminate the revolutionary potential of in silico simulation in not only 3D printed devices but also medical technology in general and biopharmaceuticals, led by field experts and thought leaders. From drug discovery to medical device design, participants will gain exclusive insights into how computational modeling and simulation reshape the landscape of healthcare innovation. Witness how virtual prototyping and predictive modeling accelerate novel therapies’ development and optimize treatment strategies. This is an event you must not miss.

Apply to speak or sponsor the event: info@3dheals.com

Subscribe here to receive event emails.

Speakers:

Simon Sonntag

Dr. Simon Sonntag, CEO & Co-Founder of Virtonomy, has been working in the medical device field for over a decade and has experienced first-hand the challenges of developing and bringing a medical device to market and in clinical practice. Using simulation technology in this field for over ten years now, he has seen the tremendous potential of combining it with digital patient twins – not only to support medical device development but also for the regulatory process and clinical trials. He learned that there is a huge demand from the industry to reduce the time, cost, and risk involved in developing medical products, and these so-called in silico methods can achieve this. Therefore, in 2020 he co-founded Virtonomy with the clear mission to change this industry. Virtonomy stands as a pioneer in the realm of digital patient twins, introducing an end-to-end platform that seamlessly merges real world patient data, artificial intelligence, multiphysics simulations, and predictive analytics to support the medical industry. Virtonomy addresses a significant problem: mitigating the elevated risks, complexities, and time constraints entailed in medical device development, ultimately streamlining the journey to market introduction. Utilizing their advanced technology, they enable medical device developers to conduct product development and testing in the computer, reducing traditional in vivo (animal/human) and in vitro (laboratory) tests with so-called in silico experiments (computer). This makes it possible to explore the interaction of the medical device with physically accurate modeling of the in vitro setup or anatomy of the target population based on real patient data as input. Backed by the FDA and EU Commission, it’s set to cover over 40% of approvals via virtual patients and simulations. The vision of Virtonomy extends to personalized medicine in the future.

Kelsey Crossman

American administrative professional with experience in Business Development in Medical Simulation and Marketing of a European Contract Research Organization managing pharmaceutical trials and medical device studies. Twelve years of experience in complex medical/administrative document management in both private and corporate medical offices and metropolitan area hospitals. Currently, she is the business development manager for Simq GmbH.

Anthony Fejes

Dr. Anthony Fejes holds undergraduate degrees in biochemistry and Independent Studies (Bioinformatics) from the University of Waterloo, as well as a Masters degree in Microbiology & Immunology and a PhD in Bioinformatics from the University of British Columbia. Anthony started his science career as the scientific co-founder and Chief Scientific Officer at Zymeworks Inc, before working for companies such as Fabric Genomics and Tenaya Therapeutics in the Bay Area and New York based SolveBio. His experience pairs over 20 years of professional experience as a programmer with a deep background in genomics, biochemistry and data analysis, as well as a decade of management and startup experience. He is CEO and co-founder at HTuO Biosciences.

Steven Kreuzer

Dr. Steven Kreuzer is a Senior Managing Engineer at Exponent Inc, a scientific and engineering consulting company, based in the Natick, MA (Boston) office. Dr. Kreuzer received his Ph.D. in Mechanical Engineering from the University of Texas at Austin and has been a consultant with Exponent since 2013. He specializes in stress analysis using both experimental and computational approaches, which include finite element analyses and custom mechanical systems. He has worked with numerous companies and projects, supporting everything from design assessments to analyses and tests supporting regulatory submissions. He has been an active participant in the Living Heart Project with Dassault Systèmes since its inception. He serves as a co-lead of the modeling team on the FDA / Dassault ‘ENRICHMENT’ in silico clinical trial. Dr. Kreuzer has applied his expertise to numerous domains, including electronics, aerospace, energy storage, and biomedical applications.

Peter Eltes

Dr. Péter Endre Éltes is a board-certified spine surgeon who has authored over 30 scientific publications and supervised multiple medical and engineering students throughout his academic career.
He has been devoted to biomechanical research and clinical practice at the National Center for Spinal Disorders in Budapest, Hungary.
In 2018, Dr. Éltes co-founded and has since led the In Silico Biomechanics Laboratory. Here, he delved into the intricate world of patient-specific spinal care with the vision of establishing novel techniques to enhance the quality of everyday clinical practice. To achieve this, he introduced various cutting-edge technologies such as surgery planning and finite element modeling, all tailored to the individual patient. Additionally, he developed and implemented a workflow to utilize 3D printing for improved patient outcomes.

Moderators:

Zsolt Pásztor

Zsolt is a passionate 3D printing specialist in titanium 3D Printing and surface treatment.
Zsolt is co-founder and Managing Director of PREMET, a 3D-printing-focused innovative medical device producer. PREMET specialises in the manufacturing of dental products and custom-made human and veterinary implants. It puts a high emphasis on R&D, covering all steps of production, and has been involved in several international projects. PREMET pays special attention to tests and simulations, including in-silico simulations. PREMET has ISO 9001 and ISO 13485 certifications.
In addition to his professional activities, Zsolt plays a leading role in different organizations. He is a Community Manager at 3DHEALS, co-founder and Vice President of the Hungarian Additive Technology Association, and Leader of the “3D Printing in the Health Sector” working group of MediKlaszter, an accredited Med Tech cluster. In MediKlaszter, he also acts as Director of International Relations.
Zsolt also has sound experience in preparing and implementing international R&D and capacity-building projects.

Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Now on Demand:

Subscribe here to receive future event emails.

Join us for an extraordinary event delving into the cutting-edge realm of 3D Bioprinting and Biofabricating Skin Components. The hair follicle is an integral part of the skin that has functions beyond aesthetics. With leading experts in the field, this event promises to unravel the innovative techniques and transformative potential of bioprinting and biofabrication in revolutionizing skin regeneration and dermatology. From advancements in tissue engineering to the intricate process of bioprinting skin components, attendees will gain invaluable insights into the future of medical technology and the future of commercializing these technologies. Discover with the Tribe at the intersection of biology and technology as pioneers in this field showcase their groundbreaking research and real-world applications. Participants will explore this technology’s promising avenues for personalized medicine, cosmetic enhancement, and wound healing through engaging presentations, interactive demonstrations, and thought-provoking discussions. Don’t miss this opportunity to be at the forefront of scientific exploration and witness the remarkable strides made towards reshaping healthcare’s future through 3D bioprinting and biofabrication of skin components.

Apply to speak or sponsor the event: info@3dheals.com

Subscribe here to receive event emails.

Time: 10:00 AM – 12:00 PM Pacific Time

Speakers:

Dr. Pankaj Karande

Dr. Pankaj Karande is an Associate Professor in Chemical and Biological Engineering at Rensselaer Polytechnic Institute. He was awarded his B.S. in Chemical Engineering from Mumbai University Institute of Chemical Technology and his Ph.D. in Chemical Engineering from the University of California, Santa Barbara. Pankaj was awarded an Anna Fuller Postdoctoral Fellowship in Molecular Oncology, and he conducted postdoctoral research in the Center for Cancer Research at Massachusetts Institute of Technology before joining the faculty at Rensselaer. Pankaj has received a variety of awards and honors in his career, including the Excellence in Classroom Instruction Award and the Outstanding Teaching Award from Rensselaer Polytechnic Institute. He also received the Alzheimer’s Association New Investigator Research Award, the Goldhirsh Brain Tumor Research Award, and a Bronze Edison Award in the Best New Product in Science and Medical Category. In addition, he has been issued multiple patents in the areas of Transdermal Formulation Discovery and Novel High Throughput Screening Platforms.

Dr. Meghan Samberg

Meghan Samberg, PhD, is the Chief Development Officer at Stemson Therapeutics where she oversees the development of tissue engineered cell therapy products that are designed for the regeneration of new hair follicles for any type and stage of hair loss. She is experienced in growing seed stage companies within the fields of regenerative and translational medicine with specialties in skin wound healing, tissue engineering, animal model development and testing, nanoparticle toxicology, biomaterial fabrication, and lyophilization. Prior to joining Stemson, Meghan simultaneously served as the VP of Clinical Affairs at ISTO Biologics, an orthobiologics company, where she led all laboratory, preclinical, and clinical research efforts, and VP & GM of Compass Biomedical, a biologics company specializing in blood-based products and therapies. In addition to serving as the PI and PM on multi-million-dollar NIH, DoD, and BARDA funded preclinical and clinical programs for Compass products, she oversaw the CDMO services for seed stage companies, translating their R&D concepts into cGMP processes and serving as their regulatory contact. Meghan holds a BS in Biological Engineering from the University of Georgia, an MS in Biomedical Engineering from Yale University, and a PhD from The University of North Carolina at Chapel Hill and North Carolina State University. She conducted post-doctoral research at NCSU and at the United States Army Institute for Surgical Research at Fort Sam Houston.

Dr. Fabien Guillemot

Dr. Fabien GUILLEMOT is a scientist-turned-entrepreneur, CEO and Founder of Poietis, whose mission is to develop and market the Next-Gen Bioprinting platform to bring Tissue Engineering therapies to patients. Fabien has an over 25 years experience in the field of Biofabrication. He holds a PhD in Material Science (INSA, 2000) and an Habilitation in Health and Life Sciences (Bordeaux University, 2010). He was appointed Researcher at INSERM, France in 2005, and invited researcher at Harvard University in 2010. Bioprinting pioneer and inventor (with 100+ publications and 13 patents), he left for entrepreneurship via training at HEC-Paris and cofounded Poietis in 2014.

Dr. Ibrahim Tarik Ozbolat

Dr. Ozbolat is a Dorothy Foehr Huck and J. Lloyd Huck Chair in 3D Bioprinting and Regenerative Medicine and Professor of Engineering Science and Mechanics Department, Biomedical Engineering Department, and Neurosurgery Department at Penn State. Dr. Ozbolat’s major research thrust is in the area of Bioprinting. His research on bioprinting for tissue and organ fabrication has been published in several high-quality venues, received various awards and has been featured in national and international media, broadcast TVs and press numerous times. He frequently gives talks at national and international forums, conferences and seminars and organizes demonstrations and events to the public and youths to encourage participation of future’s engineers in medicine, engineering and science.

Moderator:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Now on Demand:

Subscribe here to receive event emails.